The effect of abatacept on T cell activation is not long-lived in vivo

Camargo da Rosa, L. , Scales, H. E. , Benson, R. A. , Brewer, J. M. , McInnes, I. B. and Garside, P. (2024) The effect of abatacept on T cell activation is not long-lived in vivo. Discovery Immunology, 3(1), kyad029. (doi: 10.1093/discim/kyad029)

Abstract

Abatacept, a co-stimulatory blocker comprising the extracellular portion of human CTLA-4 linked to the Fc region of IgG1, is approved for the treatment of rheumatoid arthritis. By impairing the interaction between CD28 on T cells and CD80/CD86 on APCs, its mechanisms of action include the suppression of follicular T helper cells (preventing the breach of self-tolerance in B cells), inhibition of cell cycle progression holding T cells in a state described as ‘induced naïve’ and reduction in DC conditioning. However, less is known about how long these inhibitory effects might last, which is a critical question for therapeutic use in patients. Herein, employing a murine model of OVA-induced DTH, we demonstrate that the effect of abatacept is short-lived in vivo and that the inhibitory effects diminish markedly when treatment is ceased.

• Item Type: Articles
• Additional Information: This research was supported by Bristol-Myers Squibb (grant OT125-273).
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: McInnes, Professor Iain and Benson, Dr Robert and Garside, Professor Paul and Brewer, Professor James and Camargo da Rosa, Dr Larissa and Scales, Dr Hannah
• Authors: Camargo da Rosa, L., Scales, H. E., Benson, R. A., Brewer, J. M., McInnes, I. B., and Garside, P.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Journal Name: Discovery Immunology
• Publisher: Oxford University Press
• ISSN: 2754-2483
• ISSN (Online): 2754-2483
• Copyright Holders: Copyright: © The Author(s) 2024
• First Published: First published in Discovery Immunology 3)10:kyad029
• Publisher Policy: Reproduced under a Creative Commons licence